BioAge Labs to Participate in TD Cowen's 45th Annual Health Care Conference

Rhea-AI Summary

BioAge Labs (Nasdaq: BIOA), a clinical-stage biopharmaceutical company focused on developing therapeutic products for metabolic diseases through aging biology, has announced its participation in TD Cowen's 45th Annual Health Care Conference.

The conference is scheduled for March 3-5, 2025, at the Boston Marriott Copley Place in Boston, MA. BioAge will engage in one-on-one meetings during the event, which features presentations, fireside chats, and panel discussions moderated by TD Cowen research team members, covering various healthcare industry aspects.

News Market Reaction – BIOA

+2.27%

1 alert

+2.27% News Effect

On the day this news was published, BIOA gained 2.27%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

RICHMOND, Calif., Feb. 20, 2025 (GLOBE NEWSWIRE) -- BioAge Labs (Nasdaq: BIOA) (“BioAge”, “the Company”), a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, today announced that the Company will participate in one-on-one meetings at TD Cowen's 45th Annual Health Care Conference.

TD Cowen's 45th Annual Health Care Conference is taking place on March 3–5, 2025, at the Boston Marriott Copley Place in Boston, MA. The conference incorporates presentations, fireside chats and innovative panel discussions, moderated by members of the TD Cowen research team, that focus on various aspects of the health care industry.

About BioAge Labs, Inc.
BioAge is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging. The company’s pipeline includes novel, orally available, brain-penetrant small-molecule NLRP3 inhibitors to treat metabolic diseases and conditions driven by neuroinflammation, as well as novel, structurally differentiated APJ agonists for metabolic disorders. BioAge’s additional preclinical programs, which leverage insights from the Company’s proprietary discovery platform built on human longevity data, address key pathways involved in metabolic aging.

Contacts
PR: Chris Patil, media@bioagelabs.com
IR: Dov Goldstein, ir@bioagelabs.com
Partnering: partnering@bioagelabs.com
Web: https://bioagelabs.com

FAQ

When is BioAge Labs (BIOA) participating in TD Cowen's Healthcare Conference 2025?

BioAge Labs will participate in TD Cowen's 45th Annual Health Care Conference from March 3-5, 2025, at the Boston Marriott Copley Place in Boston, MA.

What type of meetings will BioAge (BIOA) conduct at the TD Cowen Conference 2025?

BioAge Labs will participate in one-on-one meetings during the TD Cowen Healthcare Conference.

What is BioAge Labs' (BIOA) current development focus in 2025?

BioAge Labs is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging.

What activities are included in TD Cowen's 45th Annual Health Care Conference where BIOA is participating?

The conference includes presentations, fireside chats, and innovative panel discussions, which are moderated by TD Cowen research team members, focusing on various aspects of the healthcare industry.